Featured Articles

  1. How The New Biotech Market Is Redefining Leadership 10/20/2025

    The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and investor relations are paramount, writes Jeff Walsh, CEO of nChroma Bio.

  2. Reading The FDA Tea Leaves On Psychedelics 10/17/2025

    MAPS founder Rick Doblin accused the FDA of changing the goal posts after Lykos's MDMA Complete Response Letter was released, and offered insights for other psychedelic developers.

  3. 100% Drug Tariffs Are A Dire Threat — And Patients Can't Wait 10/15/2025

    Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, writes BioNJ president and CEO Debbie Hart.

  4. Patients And Industry Need A New Model For Rare Disease Gene Therapy 10/10/2025

    October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug development model, writes Silvia Cerolini.  

  5. Partnering To Commercialize Radiopharmaceuticals 10/9/2025

    For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new products.

  6. Why I Love Working With Leaders Who Have 'Rounded Corners' 10/6/2025

    Life science leaders with 'rounded corners' lead to more enduring progress than razor-sharp perfection ever could, writes Tara Miller, founding partner at Artemis Factor.

  7. An Updated View Of The Federal Segment: Access Levers For Manufacturers 10/2/2025

    The third and final part of a series aimed at helping drug and device makers navigate the U.S. Veterans Affairs and Department of Defense health systems.

  8. Early-Stage Life Sciences Partnerships Raise Later-Stage Considerations 9/25/2025

    Emerging biotechs and their investors are exploring partnerships with drug companies at much earlier stages. Experts at Sidley Austin discuss key considerations for structuring partnership agreements.

  9. Pharma Direct-To-Patient 2.0: From Experiment To Imperative 9/23/2025

    Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access, according to Deepak Thomas and Sari Kaganoff.

  10. Strategic Approaches To Reducing Legal Spend Without Compromising Quality 9/19/2025

    Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences companies real money on legal expenses, writes Snell & Wilmer's April Wurster.